Status:
UNKNOWN
Aberrant Expression of Micro RNA for Diagnosis of Breast Cancer
Lead Sponsor:
Assiut University
Conditions:
Breast Cancer
Eligibility:
FEMALE
20+ years
Brief Summary
In this study we aim to: 1. Assess serum miRNA-373, miRNA-425-5p expression in patients with breast cancer. 2. Explore their correlations with breast cancer clinicopathological documented data includ...
Detailed Description
Breast cancer (BC) is the leading cause of cancer worldwide with estimated 2.3 million new cases and 685000 deaths in 2020. In women, breast cancer accounts for one in 4 cancer cases and one in 6 canc...
Eligibility Criteria
Inclusion
- Female age 20 years or older
- documented diagnosis of breast cancer based on physical examination, imaging and histopathology
- possibility of obtaining blood samples from the subject.
Exclusion
- All patients with prior history of exposure to chemotherapy, radiotherapy or hormonal therapy .
- patients with other malignancies.
- patients with chronic inflammatory diseases.
- patients with missed documentation for histopathological diagnosis of breast cancer.
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 25 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04720508
Start Date
December 1 2021
End Date
December 25 2023
Last Update
January 22 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.